Trial Profile

A Phase I, Open Label, Dose Escalation Study of ACE1702 Cell Immunotherapy in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ACE 1702 (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Sponsors Acepodia

Most Recent Events

22 Jun 2022 Planned End Date changed from 1 Jul 2022 to 1 Jun 2024.
22 Jun 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Jun 2024.
16 Sep 2021 According to an Acepodia media release, interim data are available to view in an on-demand e-Poster (presentation number 1006P) as part of the 2021 European Society of Medical Oncology (ESMO) 2021 Virtual Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com